Limarin® LIMARIN® (Silymarin Capsules) LIMARIN® Suspension (Silymarin Suspension)

LIMARIN^® Suspension
Each 5 ml (One teaspoonful) contains Silymarin 35mg in a flavoured base.

Colour : Sunset Yellow

Chemistry :
Silymarin contains three main components (Flavonolignans) namely Silybinin, Silycristin and Silydianin.

Description :

• Therapeutic Class of Drug: Hepatoprotective (7, 8 Dihydroxyflaone)
  
  
• Chemical Group: LIMARIN^® contains the active principle from the fruit of silybum marianum. The principle components are the flavonolignans, silibinin, silicristin and silidanin of which silibinin is the major component.
  
  
• Development History: LIMARIN^® is developed from the active extract of the fruit of silybum marianum, or the milk thistle. Basically a European herbal product, well researched even in the USA.
  

Pharmacological Actions :

LIMARIN^® has a potent hepatoprotective effect by various mechanisms facilitating physiology and metabolism of hepatocytes. Free radical scavenging (antioxidant) action is via the glutathione system and superoxide dismutase. LIMARIN stimulates synthesis of polymerase l, enhances ribosomal protein synthesis and exerts a membrane stabilising effect.

LIMARIN^® also reduces prostaglandin Synthesis.

LIMARIN^® is known for its hepatoprotective action against hepatic glutathione depletion induced by ethyl alcohol and paracetamol in animal studies.

LIMARIN^® reduces the turnover of membrane phospholipids and stabilises both extra and intracellular membranes inside hepatocytes.

LIMARIN^® also increases the phagocytic activity of the Kupffer cells, contributing to hepatoprotective and regenerative effects.

Pharmacokinetics :
LIMARIN^®is absorbed to the extent of about 50% following an oral dose. The major ingredient, Silibinin, is concentrated in the liver, reaches high concentration in the bile; almost 30 times that in plasma; peak levels are attained 2-8 hrs. following oral dose. Systemic half life is about 6.5 hrs. Main route of elimination is through the bile.

Drug Disease Interactions:
None specific.

Drug Drug Interaction:
None reported so far.

Indications:

• In patients with liver disorders, specially Hepatitis A.
  
  
• Effective in preventing hepatic damage due to amanita poisoning.
  
  
• In Cirrhosis of liver, Chronic hepatitis, Alcoholic liver disease, Drug induced liver damage and Fatty degeneration of the liver in diabetics
  
  
• Supportive treatment in Alcoholic hepatitis, Chronic Active Hepatitis, Infective Hepatitis A, Infective Hepatitis B, Cirrhosis of the liver and Toxic liver damage due to drugs and toxins

Clinical Safety/Tolerability:
Hypersensitivity may occur; mild laxative effect has been reported.

Special Safety Considerations:
Uneventful use in pregnancy has been recorded. However, large scale safety studies have not been conducted.

Pregnancy:
Safety in pregnancy has not been established.

Lactation:
Safety in lactation has not been established. Use in pregnancy and lactation is not recommended.

Side Effects:
Mild laxative effects.

Adverse Effects/Reactions:
Not reported.

Toxicological Effects:
Not reported.

Warnings:
Weigh risk benefit ratio before use in pregnancy and lactation

Precautions:
None reported

Contraindications:
None reported

Dosage and Administration:
LIMARIN^®Capsules
Hepatitis A : LIMARIN^® 140 mg, one capsule thrice daily for 1 month.

Alcoholic Liver disease and other indications : LIMARIN^®140 mg, one capsule thrice daily for 3-6 months or as directed by the Physician.

Maintenance dose : LIMARIN^®70 mg, one capsule thrice daily or as directed by the Physician.

LIMARIN^®SUSPENSION
Mild to moderate : 10mg/kg body weight in 3 divided doses.

Severe : 20 mg/kg body weight in 3 divided doses.


PATIENT INSTRUCTIONS
Report to your doctor if any rash or itching or irritation occurs .